JP6552608B2 - ヒストンデメチラーゼ阻害剤 - Google Patents

ヒストンデメチラーゼ阻害剤 Download PDF

Info

Publication number
JP6552608B2
JP6552608B2 JP2017514615A JP2017514615A JP6552608B2 JP 6552608 B2 JP6552608 B2 JP 6552608B2 JP 2017514615 A JP2017514615 A JP 2017514615A JP 2017514615 A JP2017514615 A JP 2017514615A JP 6552608 B2 JP6552608 B2 JP 6552608B2
Authority
JP
Japan
Prior art keywords
pyrimidin
pharmaceutically acceptable
pyrido
acceptable salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017514615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529346A5 (enExample
JP2017529346A (ja
Inventor
ボロアー,アモフ
カノウニ,トウフィケ
スタッフォード,ジェフリー,アラン
ヴィール,ジェイムス,マービン
ブレナン ウォレス,マイケル
ブレナン ウォレス,マイケル
Original Assignee
セルジーン クオンティセル リサーチ,インク.
セルジーン クオンティセル リサーチ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン クオンティセル リサーチ,インク., セルジーン クオンティセル リサーチ,インク. filed Critical セルジーン クオンティセル リサーチ,インク.
Publication of JP2017529346A publication Critical patent/JP2017529346A/ja
Publication of JP2017529346A5 publication Critical patent/JP2017529346A5/ja
Application granted granted Critical
Publication of JP6552608B2 publication Critical patent/JP6552608B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017514615A 2014-09-17 2015-09-16 ヒストンデメチラーゼ阻害剤 Expired - Fee Related JP6552608B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051691P 2014-09-17 2014-09-17
US62/051,691 2014-09-17
PCT/US2015/050432 WO2016044429A1 (en) 2014-09-17 2015-09-16 Histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2017529346A JP2017529346A (ja) 2017-10-05
JP2017529346A5 JP2017529346A5 (enExample) 2018-10-25
JP6552608B2 true JP6552608B2 (ja) 2019-07-31

Family

ID=55525128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514615A Expired - Fee Related JP6552608B2 (ja) 2014-09-17 2015-09-16 ヒストンデメチラーゼ阻害剤

Country Status (17)

Country Link
US (7) US9643965B2 (enExample)
EP (2) EP3193601B1 (enExample)
JP (1) JP6552608B2 (enExample)
KR (1) KR20170048591A (enExample)
CN (1) CN107205391A (enExample)
AU (1) AU2015317806A1 (enExample)
BR (1) BR112017005511A2 (enExample)
CA (1) CA2961610A1 (enExample)
CL (1) CL2017000659A1 (enExample)
CO (1) CO2017003538A2 (enExample)
EA (1) EA201790603A1 (enExample)
EC (1) ECSP17023551A (enExample)
ES (1) ES2910226T3 (enExample)
IL (1) IL251179A0 (enExample)
MX (1) MX2017003466A (enExample)
SG (1) SG11201702147TA (enExample)
WO (1) WO2016044429A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508452A (ja) * 2016-03-15 2019-03-28 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
US11535616B2 (en) 2014-09-17 2022-12-27 Celgene Quanticel Research, Inc Histone demethylase inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970211T (pt) 2013-03-15 2017-10-31 Quanticel Pharmaceuticals Inc Inibidores de histona demetilase
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MA45887B1 (fr) 2016-11-28 2021-04-30 Teijin Pharma Ltd Cristal de dérivé de pyrido [3, 4-d] pyrimidine ou son solvate
US11040973B2 (en) 2017-03-29 2021-06-22 Purdue Research Foundation Inhibitors of kinase networks and uses thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116253712B (zh) * 2023-03-27 2025-05-02 昆山市第一人民医院 5,6,7-三甲氧基-2,3-二氢喹啉类化合物、药物组合物及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4383870B2 (ja) * 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
WO2006036395A2 (en) * 2004-08-23 2006-04-06 Merck & Co., Inc. Inhibitors of akt activity
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
JP5552608B2 (ja) 2012-04-27 2014-07-16 株式会社ソフイア 遊技機
HUE033380T2 (en) 2012-10-02 2017-11-28 Gilead Sciences Inc Inhibitors of histone demethylases
SMT201800070T1 (it) 2012-12-19 2018-03-08 Celgene Quanticel Res Inc Inibiorti di istone demetilasi
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
PT2970211T (pt) 2013-03-15 2017-10-31 Quanticel Pharmaceuticals Inc Inibidores de histona demetilase
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
AR100997A1 (es) 2014-06-25 2016-11-16 Quanticel Pharmaceuticals Inc Derivados de piridina como inhibidores de histona demetilasa
MX2017003466A (es) 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3430008B1 (en) 2016-03-15 2022-05-18 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535616B2 (en) 2014-09-17 2022-12-27 Celgene Quanticel Research, Inc Histone demethylase inhibitors
JP2019508452A (ja) * 2016-03-15 2019-03-28 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤

Also Published As

Publication number Publication date
MX2017003466A (es) 2017-07-13
AU2015317806A1 (en) 2017-04-13
KR20170048591A (ko) 2017-05-08
US20210009585A1 (en) 2021-01-14
CN107205391A (zh) 2017-09-26
ECSP17023551A (es) 2017-05-31
ES2910226T3 (es) 2022-05-12
EP3193601A4 (en) 2018-07-04
EP3193601B1 (en) 2022-01-05
CA2961610A1 (en) 2016-03-24
US20170240546A1 (en) 2017-08-24
US20230117519A1 (en) 2023-04-20
US11535616B2 (en) 2022-12-27
US20160083379A1 (en) 2016-03-24
CL2017000659A1 (es) 2018-05-11
US20200199122A1 (en) 2020-06-25
JP2017529346A (ja) 2017-10-05
EP3453710B1 (en) 2022-09-21
WO2016044429A1 (en) 2016-03-24
US10112940B2 (en) 2018-10-30
US20190023704A1 (en) 2019-01-24
SG11201702147TA (en) 2017-04-27
US12172998B2 (en) 2024-12-24
IL251179A0 (en) 2017-05-29
EP3193601A1 (en) 2017-07-26
EA201790603A1 (ru) 2017-10-31
BR112017005511A2 (pt) 2018-08-14
US10611763B2 (en) 2020-04-07
CO2017003538A2 (es) 2017-07-28
EP3453710A1 (en) 2019-03-13
US10815234B2 (en) 2020-10-27
US9643965B2 (en) 2017-05-09
US20250066355A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP6552608B2 (ja) ヒストンデメチラーゼ阻害剤
US10494369B2 (en) Histone demethylase inhibitors
US10202381B2 (en) Histone demethylase inhibitors
JP6970681B2 (ja) ヒストンデメチラーゼ阻害剤
JP2017529347A (ja) ヒストンデメチラーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190702

R150 Certificate of patent or registration of utility model

Ref document number: 6552608

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees